GPR30 Inhibitors
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Estriol | 50-27-1 | sc-205682 sc-205682A | 100 mg 500 mg | $21.00 $65.00 | ||
Estriol functions as a GPR30 inhibitor, characterized by its selective binding affinity that engages in specific electrostatic interactions with the receptor's active site. This compound demonstrates a rapid kinetic profile, facilitating quick receptor occupancy and subsequent modulation of downstream signaling pathways. Its unique three-dimensional structure allows for distinct conformational changes in GPR30, potentially influencing cellular responses and regulatory mechanisms. The compound's solubility properties further enhance its interaction dynamics within biological systems. | ||||||
GSK 4716 | 101574-65-6 | sc-203986 sc-203986A | 10 mg 50 mg | $71.00 $285.00 | ||
GSK4716 is a GPR30 antagonist that competes with endogenous ligands for binding to the receptor. This competition results in the inhibition of GPR30-mediated signaling pathways, particularly the cAMP/PKA and PI3K/Akt pathways. GSK4716's mechanism of action involves disrupting the normal activation of GPR30, making it a reliable chemical for investigating the functional roles of GPR30 in various cellular contexts. | ||||||
ICI 182,780 | 129453-61-8 | sc-203435 sc-203435A | 1 mg 10 mg | $83.00 $187.00 | 34 | |
Fulvestrant, classified as a selective estrogen receptor degrader (SERD), indirectly inhibits GPR30. By promoting the degradation of estrogen receptors, including GPR30, Fulvestrant reduces the availability of functional receptors for activation. This results in a comprehensive attenuation of GPR30-mediated signaling cascades, impacting pathways such as PI3K/Akt and ERK1/2. Fulvestrant's dual mechanism offers insights into the intricate regulation of estrogen signaling pathways. | ||||||
β-Estradiol | 50-28-2 | sc-204431 sc-204431A | 500 mg 5 g | $63.00 $182.00 | 8 | |
While traditionally recognized as an estrogen hormone, estradiol can also exert antagonist effects on GPR30. In certain contexts, high concentrations of estradiol can compete with endogenous ligands for GPR30 binding, leading to the inhibition of its normal activation. This results in the modulation of GPR30-mediated signaling pathways, including the regulation of cAMP/PKA and calcium signaling, highlighting the intricate dual role of estradiol in estrogen receptor modulation. | ||||||
GSK 429286 | 864082-47-3 | sc-361200 sc-361200B sc-361200A | 1 mg 5 mg 10 mg | $40.00 $125.00 $235.00 | ||
GPR30 Inhibitor 1 is a small molecule antagonist designed to specifically target and inhibit GPR30. By binding to the receptor, this inhibitor disrupts GPR30-mediated signaling pathways, affecting downstream effectors such as MAPK and PI3K/Akt. The compound's design ensures high selectivity for GPR30, making it a valuable tool in elucidating the nuanced roles of GPR30 in various cellular processes and its potential implications in health and disease. | ||||||
(Z)-4-Hydroxytamoxifen | 68047-06-3 | sc-3542C sc-3542 sc-3542B sc-3542A sc-3542D sc-3542E | 1 mg 5 mg 10 mg 25 mg 50 mg 100 mg | $220.00 $281.00 $408.00 $718.00 $1377.00 $2397.00 | 20 | |
GPR30 Inhibitor 2 is a chemical compound designed for the specific inhibition of GPR30. Its mechanism involves interfering with the receptor's activation and subsequent downstream signaling. This inhibitor particularly impacts GPR30-mediated pathways like cAMP/PKA and MAPK. The structural features of GPR30 Inhibitor 2 contribute to its selectivity, making it an essential tool for researchers investigating the molecular intricacies of GPR30 function in diverse cellular contexts. | ||||||